Clinical outcome by study (TT2 vs TT1) in relationship to presence or absence of cytogenetic abnormalities (CAs). (A) Cumulative incidence of CR: frequency of CR was similar between patients with and without CAs for TT1. TT2 patients with CAs had a lower frequency of CR than patients without CAs. (B) Event-free survival: TT2 improves EFS for both patients with and without CAs. (C) Overall survival: TT2 improves OS only for patients without CAs.